Empathy Detection Using Machine Learning on Text, Audiovisual, Audio or Physiological Signals

Empathy is a social skill that indicates an individual's ability to understand others. Over the past few years, empathy has drawn attention from various disciplines, including but not limited to Affective Computing, Cognitive Science and Psychology. Empathy is a context-dependent term; thus, detecting or recognising empathy has potential applications in society, healthcare and education. Despite being a broad and overlapping topic, the avenue of empathy detection studies leveraging Machine Learning remains underexplored from a holistic literature perspective. To this end, we systematically collect and screen 801 papers from 10 well-known databases and analyse the selected 54 papers. We group the papers based on input modalities of empathy detection systems, i.e., text, audiovisual, audio and physiological signals. We examine modality-specific pre-processing and network architecture design protocols, popular dataset descriptions and availability details, and evaluation protocols. We further discuss the potential applications, deployment challenges and research gaps in the Affective Computing-based empathy domain, which can facilitate new avenues of exploration. We believe that our work is a stepping stone to developing a privacy-preserving and unbiased empathic system inclusive of culture, diversity and multilingualism that can be deployed in practice to enhance the overall well-being of human life

Pavlok-Nudge: A Feedback Mechanism for Atomic Behaviour Modification with Snoring Usecase

This paper proposes a feedback mechanism to 'break bad habits' using the Pavlok device. Pavlok utilises beeps, vibration and shocks as a mode of aversion technique to help individuals with behaviour modification. While the device can be useful in certain periodic daily life situations, like alarms and exercise notifications, the device relies on manual operations that limit its usage. To this end, we design a user interface to generate an automatic feedback mechanism that integrates Pavlok and a deep learning based model to detect certain behaviours via an integrated user interface i.e. mobile or desktop application. Our proposed solution is implemented and verified in the context of snoring, which first detects audio from the environment following a prediction of whether the audio content is a snore or not. Based on the prediction of the deep learning model, we use Pavlok to alert users for preventive measures. We believe that this simple solution can help people to change their atomic habits, which may lead to long-term benefits.Comment: Shreya Ghosh, Rakibul Hasan and Pradyumna Agrawal contributed equally to this researc

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo